DSM verkoop belang in medicijnfabrikant Patheon voor 1,5 miljard euro

Al enige jaren behoort farmacie niet meer tot de strategische activiteiten van DSM. Het bedrijf stoot daarom al zijn belangen in medicijnproducenten af.

Het Amerikaanse Thermo Fisher Scientist neemt voor 1,7 miljard euro DSM’s belang in Patheon over. Dat bedrijf maakt medicijnen voor anderen.

Aan de deal houdt DSM 1,5 miljard euro over.

DSM is nu nog voor de helft eigenaar van Sinochem Fharmaceuticals, dat onder meer antibiotica maakt. Ook dat belang staat te koop.

 

DSM informs market on Patheon N.V.
Royal DSM, a global science-based company active in health, nutrition and materials, informs its stakeholders that the Board of Directors of Patheon N.V. (NYSE:PTHN), a company in which DSM holds approximately 48.7 million ordinary shares, has unanimously approved the acquisition of Patheon by Thermo Fisher Scientific Inc. (NYSE:TMO). Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per ordinary share in cash.

DSM has entered into a tender and support agreement with Thermo Fisher pursuant to which DSM will tender its shares in the transaction. The transaction, which is expected to be completed by the end of 2017, is subject to the satisfaction of customary closing conditions, including the receipt of applicable regulatory approvals, the adoption of certain resolutions relating to the transaction at an extraordinary general meeting of Patheon’s shareholders and completion of the tender offer.

More information regarding the acquisition of Patheon by Thermo Fisher can be found in the press release issued by Thermo Fisher and Patheon on 15 May 2017.